Anthem Biosciences Ltd

Anthem Biosciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Anthem Biosciences Ltd is rated Buy by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 02 June 2026, providing investors with the latest insights into its fundamentals, returns, and overall market stance.

Anthem Biosciences Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a bullish trend. This change, coupled with an upgrade in its Mojo Grade from Sell to Buy, reflects improving market sentiment and potential upside for investors in the Pharmaceuticals & Biotechnology sector.

Anthem Biosciences Ltd has seen a significant upgrade in its investment rating from Sell to Buy as of 21 May 2026, driven by marked improvements across financial performance, quality metrics, valuation considerations, and technical indicators. This mid-cap pharmaceutical and biotechnology company’s recent quarterly results and long-term fundamentals have prompted a reassessment of its prospects, positioning it favourably against sector peers and broader market benchmarks.

Anthem Biosciences Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its business fundamentals. The pharmaceutical and biotechnology company’s robust sales and EBIT growth, alongside stellar returns on capital and equity, underpin this positive reassessment. Despite a slight dip in share price, the company’s financial health and operational efficiency position it favourably against peers and broader market benchmarks.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics.

Anthem Biosciences Ltd., a mid-cap pharmaceuticals and biotechnology company with a market capitalisation of ₹45,142 crores, delivered a blockbuster performance in Q4 FY26 (March 2026 quarter), posting net profit of ₹189.76 crores—a stunning 104.44% surge quarter-on-quarter and 129.68% year-on-year growth. However, the stock declined 0.87% to ₹780.25 following the results announcement, reflecting investor concerns over stretched valuations despite the impressive operational performance.

The 50-day moving average has crossed above the 200-day moving average for Anthem Biosciences Ltd, signalling a golden cross on 20 May 2026. Yet, the stock declined 0.87% on the day the cross formed, while monthly technical indicators remain inconclusive. This divergence between the moving averages and other signals calls for a nuanced analysis of the cross's reliability.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest.

Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 12 May 2026, reflecting a combination of improved technical indicators, solid management efficiency, and a cautiously optimistic outlook despite recent quarterly financial setbacks. The mid-cap pharmaceutical company’s Mojo Score now stands at 50.0, signalling a more balanced risk-reward profile for investors.

Anthem Biosciences Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical signals that suggest a mild uptrend after a period of sideways movement. The company’s stock price has gained 2.08% today, closing at ₹800.30, reflecting renewed investor interest amid improving technical indicators.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a modest day change of -0.07%, the stock’s technical indicators present a complex picture, with bullish signals on weekly MACD and Bollinger Bands contrasting with neutral or bearish cues on monthly charts and volume-based metrics. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex.

Anthem Biosciences Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a combination of bullish weekly MACD and Bollinger Bands signals, alongside mixed monthly indicators and a recent downgrade in its Mojo Grade from Hold to Sell, reflecting a complex market outlook for this mid-cap pharmaceutical player.